Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples